Andrew Hendifar, MD, and Robert Figlin, MD, discuss highlights from the 2021 ASCO annual meeting, including immunotherapy in MSI-H/dMMR metastatic CRC patients, looking for DEEPER responses in RAS-wild type tumors, the need for testing for HER2+ CRC patients, and liquid biopsy and the CHRONOS trial.